Sam Brusco - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Sam Brusco's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Sam Brusco
Verified
Associate Editor, (ODT) Orthopedic Design & Technology Magazine
Riverdale
Beats
Representation In Film , Body Positivity, parenthood mental health, feminism anti-racism, asian american identity
I'm open to anything in the outdoor space, but I avoid pseudo-science.
Content
By Sam Brusco Verified| Medical Product Outsourcing Verified Adagio Medical Holdings, a company focused on catheter ablation tech to treat cardiac arrhythmias, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its vCLAS cryoablation system to treat drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (VT) in patients with ischemic or non-ischemic structural heart disease. vCLAS is currently amid the FULCRUM-VT investigational device exemption (IDE) study.
By Sam Brusco Verified| Medical Product Outsourcing Verified EBR Systems has received U.S. Food and Drug Administration (FDA) approval for the WiSE system, the first, only CRT device that delivers leadless left ventricular endocardial pacing (LVEP) that closely aligns with the heart’s natural conduction pathway. This endocardial approach reflects a more physiological method of resynchronization and lets electrophysiologists treat patients that can’t receive lead-based devices.
By Sam Brusco Verified| Medical Product Outsourcing Verified Adagio Medical Holdings, a company focused on catheter ablation tech to treat cardiac arrhythmias, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its vCLAS cryoablation system to treat drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (VT) in patients with ischemic or non-ischemic structural heart disease. vCLAS is currently amid the FULCRUM-VT investigational device exemption (IDE) study.
Company Info
(ODT) Orthopedic Design & Technology Magazine